Bladerunner, do your own reading on the economics of generic drug markets. Either Sanofi will do what it and its peers have always done, or they won't. What they have always done is raise their prices and let the generics fight it out below.
And before you get to it, this is not a usual generic market. Lovenox will not have many generic entrants,and TEVA's entrance is not at all ensured at all. So read it in the context of this first time, unique, generic, not the run of the mill small molecule generic as studied by this article.
Afterwards, you can decide for yourself if Sanofi will get into a price war or do what it always has done. That is up to Sanofi.
Market Data 
Markets 
AI
